Clinical trials: Hepatocellular Cancer
Hepatic Carcinoma
Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function
The purpose of this study is to investigate the safety and efficacy of irreversible electroporation for unresectable Hepatic carcinoma in poor liver function, also Progress Free Survival (PFS) and Over Survival (OS) will be…
- Trial name
- NCT02352935
- Testing
- NanoKnife LEDC System
- Where
- China
- Volunteers
- 15 people
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Hepatocellular Carcinoma
Study of TG02 Citrate in Patients With Advanced Hepatocellular Carcinoma
This is a single-centre, open-label, dose escalation, Phase 1 study. The primary objective is to determine the highest dose of TG02 citrate that can safely be given to patients with advanced hepatocellular carcinoma.
- Trial name
- NCT03738111
- Testing
- TG02 Citrate
- Sponsor
- Lee's Pharmaceutical Limited
Hepatocellular Carcinoma
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
A clinical trial to compare the pharmacokinetics and bioequivalence of BR2008 with BR2008-1 in healthy volunteers
- Trial name
- NCT05068193
- Testing
- BR2008-1 (R), BR2008 (T)
- Where
- South Korea
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hepatocellular Carcinoma
A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-141 at varying dose levels and frequencies.
- Trial name
- NCT01733004
- Testing
- MM-141
- Where
- 4 sites in United States, France
- Volunteers
- 42 people
- Sponsor
- Merrimack Pharmaceuticals
Hepatocellular Carcinoma (HCC)
TACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
The safety, clinical efficacy and prognostic factors of transcatheter arterial chemoembolization (TACE) and/or hepatic artery infusion chemotherapy (HAIC) combined with targeted immunotherapy for primary hepatocellular carcinoma…
- Trial name
- NCT07658833
- Testing
- TACE (transarterial chemoembolization) combined with targeted/immunotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma
Efficacy of Sequential TACE and PVE on the Resectability of Hepatitis B Related HCC
A primary hepatocellular carcinoma (HCC) is generally regarded as unresectable if the future liver remnant (FLR)≤40％ of total liver volume in patient with underlying liver disease, such as hepatitis B.
- Trial name
- TACEPVE (NCT00834158)
- Testing
- TACE, PVE
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Solid Tumor, Solid Carcinoma
Trop2-targeted immunoPET Imaging of Solid Tumors
This study aims to establish and optimize the trophoblast cell surface antigen 2 (Trop2)-targeted immuno-positron emission tomography/computed tomography (immunoPET/CT) imaging method and its physiological and pathological…
- Conditions
- Solid Tumor, Solid Carcinoma, Uroepithelial Carcinoma, Bladder Cancer
- Trial name
- NCT06851663
- Testing
- [68Ga]Ga-NOTA-T4, [68Ga]Ga-NOTA-RT4, [18F]F-RESCA-T4
- Where
- China
- Volunteers
- 400 people
- Sponsor
- RenJi Hospital
Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced Biliary, Pancreatic, Urothelial, or Non-Small Cell Lung Cancer
This phase I clinical trial is studying the side effects and best dose of veliparib and gemcitabine hydrochloride when given with cisplatin in treating patients with advanced biliary, pancreatic, urothelial, or non-small cell…
- Conditions
- Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter
- Trial name
- NCT01282333
- Testing
- gemcitabine hydrochloride, veliparib, diagnostic laboratory biomarker analysis
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Cancer, Metastases
Gadofosveset Trisodium (Ablavar, Gdfos) in Distinguishing Hemangiomas and Metastases: A Prospective Trial
The purpose of this study is to determine if Gadofosveset Trisodium (Gdfos, Ablavar) is a useful magnetic resonance imaging (MRI) contrast agent in accurately diagnosing liver metastases compared to the standard agent gadobutrol…
- Conditions
- Cancer, Metastases, Liver Neoplasms
- Trial name
- NCT02036008
- Testing
- Liver MRI with Gdfos, Liver MRI with EcGd
- Where
- Canada
- Volunteers
- 150 people
- Sponsor
- Sunnybrook Health Sciences Centre
Hepatocellular Carcinoma
Ablation Combined With PD-1 in HCC: Phase II Study
This is a Phase 2, single arm, single center study designed to evaluate the safety and tolerability of radiofrequency or microwave ablation combined with PD-1 monoclonal antibody in patients with hepatocellular carcinoma(HCC)…
- Trial name
- NCT04652440
- Testing
- PD-1 monoclonal antibody, Radiofequencey or microwave ablation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Advanced Adult Hepatocellular Carcinoma
An Individualized Anti-Cancer Vaccine in Advanced Hepatocellular Carcinoma Subjects
This is an open-label, single site, Phase IIA clinical trial to investigate the safety and efficacy of an individualized anti-cancer vaccine (CRCL-AlloVax) in advanced HCC patients.
- Trial name
- NCT02409524
- Testing
- AlloVax, AlloStim, CRCL
- Where
- Thailand
- Volunteers
- 15 people
- Sponsor
- Mirror Biologics, Inc.
Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi
TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis
In this study, single cell transcriptome sequencing will be performed on the tissue samples punctured and the surgically resected specimens to explore the gene mutation sites related to efficacy
- Trial name
- NCT04888546
- Testing
- Anlotinib hydrochloride capsules＋ TQB2450 injection
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese Academy of Medical Sciences
Infection
Telaprevir Plus Standard of Care (SOC) in HCV Associated Hepatocellular Carcinoma (HCC)
The goal of this clinical research study is to learn if the antiviral combination of telaprevir, pegylated Interferon Alfa 2a (PegIFN alfa-2a) and ribavirin (RBV) can prevent the virus from coming back after the liver transplant.
- Trial name
- NCT01821963
- Testing
- Pegylated Interferon Alfa 2a, Ribavirin, Telaprevir
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- M.D. Anderson Cancer Center
Hepatocellular Carcinoma, Microwave Ablation
Donafenib as Adjuvant Therapy Following Ablation for Recurrent HCC
This study intends to evaluate the efficacy and safety of low-dose adjuvant donafenib after thermal ablation for early recurrent HCC within Milan criteria.
- Conditions
- Hepatocellular Carcinoma, Microwave Ablation, Donafenib, Recurrent Tumor
- Trial name
- NCT06609876
- Testing
- Thermal ablation, Donafenib
- Where
- China
- Volunteers
- 108 people
- Sponsor
- Sun Yat-sen University
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
3-Tesla MRI Response to TACE in HCC (Liver Cancer)
This pilot clinical trial examines how well different imaging biomarkers acquired using 3-Telsa magnetic resonance imaging (MRI) methods perform in determining treatment response to transarterial chemoembolization (TACE) in…
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Resectable Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer
- Trial name
- NCT02057874
- Testing
- 3 Tesla Magnetic Resonance Imaging, Magnevist® (Intravenous (IV) administration of MRI contrast agent)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Advanced Hepatocellular Carcinoma (HCC), Metastatic Liver Cancer
Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC
open-label trial of an allogeneic dual-target CAR-NK product directed against GPC3 and B7-H3 for adults with advanced hepatocellular carcinoma.
- Trial name
- DUET-HCC (NCT07500220)
- Testing
- EB-G3B7-NK dual-target CAR-NK cells, Fludarabine, Cyclophosphamide
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Beijing Biotech
Hepatocellular Carcinoma (HCC)
Artificially Intelligent Model for Accurate Detection of HCC
Purpose: Integrating comprehensive information on hepatocellular carcinoma (HCC) is essential to improve its early detection. The investigators aimed to develop a model with multi-modal features (MMF) using artificial…
- Trial name
- NCT06637059
- Testing
- observational study
- Where
- China
- Volunteers
- 1,092 people
- Sponsor
- Zhejiang University
Liver Diseases, Hepatocellular Carcinoma
bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC
This study intends to evaluate the efficacy and safety of blank- microsphere transcatheter arterial embolization-hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin (bTAE-HAIC) plus Lenvatinib and…
- Conditions
- Liver Diseases, Hepatocellular Carcinoma, Immunotherapy, Camrelizumab
- Trial name
- NCT06061276
- Testing
- bTAE-HAIC, Lenvatinib, Camrelizumab
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
GPC3 Targeted Fluorescence Image Guided Surgery of Hepatocellular Carcinoma
This study is to evaluate whether intraoperative fluorescence imaging targeting GPC3 can aid improve the surgical accuracy of hepatocellular carcinoma.
- Trial name
- NCT05047510
- Testing
- Anti-GPC3-IRDye800CW
- Where
- 2 sites in China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Chinese Academy of Sciences
Hepatocellular Carcinoma
A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC)
The main purpose of this study is to evaluate safety and tolerability of LY2157299 when combined with sorafenib in Japanese hepatocellular carcinoma (HCC) participants.
- Trial name
- NCT02240433
- Testing
- LY2157299, Sorafenib
- Where
- 3 sites in Japan
- Volunteers
- 9 people
- Sponsor
- Eli Lilly and Company